Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.
d'Andrea G, Chiappini S, Ciavoni L, Tucci R, Martino F, Semeraro FM, Di Battista D, Mosca A, Miuli A, Di Carlo F, Russo M, Di Petta G, Fornaro M, Pettorruso M, Sensi SL, Martinotti G.
d'Andrea G, et al.
Transl Psychiatry. 2025 Oct 31;15(1):453. doi: 10.1038/s41398-025-03654-3.
Transl Psychiatry. 2025.
PMID: 41173871
Free PMC article.
While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are increasingly used to manage treatment-resistant depression. ...From the total of 49 studies, 9 were randomized-controlled trials, 25 were open-label studi …
While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are increasingly used to …